SCHEMBL6965041

SCHEMBL6965041

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc2c(N(Cl)C(=N)N)cncc2c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 10/20 0.35
TMPRSS6 Q8IU80 4/20 0.35
PLAU P00749 3/20 0.35
ACACB O00763 1/20 0.34
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 2/20 0.33
F10 P00742 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
SCN9A Q15858 1/20 0.31
PLG P00747 1/20 0.31
PLAT P00750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6432755 0.99 F2 (0.35) F2TMPRSS6PLAUACACBALDH1A1
SCHEMBL6433064 0.91 S1PR1 (0.38) F2TMPRSS6PLAUACACBALDH1A1
SCHEMBL6433416 0.85 PLAU (0.32) F2PLAUF10PLG
SCHEMBL6434466 0.84 NR1D1 (0.35) PLAU
SCHEMBL7050063 0.84 PLAU (0.38) PLAUALDH1A1KDM4EGAAMAPT
SCHEMBL6434837 0.83 PLAU (0.37) PLAUACACBALDH1A1KDM4ESCN9A
Hydrochloric Acid SCHEMBL6433670 0.83 PLAU (0.51) F2PLAUSCN9APLGPLAT
Trifluoroacetic Acid SCHEMBL7369183 0.83 PLAU (0.43) F2TMPRSS6PLAUALDH1A1KDM4E
SCHEMBL6437619 0.82 PTPRC (0.42) F2KDM4EMAPTF10
Hydrochloric Acid SCHEMBL6439059 0.81 PLAU (0.40) F2PLAUSMN1; SMN2F10PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 F2 350/4885TMPRSS6 543/4885PLAU 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.